Netflix shared the first image from Rian Johnson's Wake Up Dead Man: A Knives Out Mystery. Here's everything else we know ...

CAMBRIDGE, Mass. - Foghorn Therapeutics Inc. (NASDAQ:FHTX), a biotechnology firm focused on developing novel medicines through gene expression correction, announced today the appointment of two ...

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...

CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious ...

Get Our Latest Research Report on FHTX Foghorn Therapeutics Stock Up 0.7 % FHTX opened at $4.39 on Tuesday. Foghorn Therapeutics Inc. has a 52 week low of $2.94 and a 52 week high of $10.25. The ...

Citizens JMP initiated coverage of Foghorn Therapeutics (FHTX) with an Outperform rating and $9 price target Foghorn is a clinical-stage biotechnology company focused on developing novel therapies ...

CAMBRIDGE, Mass. - Foghorn Therapeutics Inc. (NASDAQ:FHTX), a biotechnology firm focused on developing novel medicines through gene expression correction, announced today the appointment of two new ...

Foghorn Therapeutics Inc. has announced the election of Dr. Neil Gallagher and Stuart Duty to its Board of Directors, aiming to enhance its strategic outlook as it advances its pipeline of novel ...

Foghorn Therapeutics Inc. announced advancements in their clinical and preclinical programs, focusing on FHD-909 (LY4050784), a selective SMARCA2 inhibitor currently in a Phase 1 trial targeting ...

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...

(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of ...